Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

new data at the ASH 2018 congress in multiple myeloma. ... One specialist cited by analysts at William Blair has predicted that neurotoxicity could prove to be a differentiating factor between BCMA-targeted therapies for myeloma.

Latest news

More from news
Approximately 43 fully matching, plus 185 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    treatment of multiple myeloma and other conditions. Joint development. agreement. $665m. ... Who’s the winner? We won’t know for many years. Multiple deals from Gilead too.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Its fourth pipeline candidate is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene, which is tipped to be Bluebird’s potential blockbuster and therefore most crucial ... This is especially likely around its multiple

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

  • Deal Watch September 2016 Deal Watch September 2016

    Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma.

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics